Novo Nordisk: Sensitivity Analysis Of Oral Wegovy's Gross Profits Supports Modest Buy

Novo Nordisk (NVO) is rated a Modest Buy with a raised price target of $80, driven by oral Wegovy’s rapid market adoption. Oral Wegovy has achieved over 3 million prescriptions in five months, with 80% from GLP-1–naïve patients, expanding the addressable market. Sensitivity analysis suggests a base case wherein oral Wegovy could generate $12–$15 billion in annual gross profit under realistic assumptions. Risks include pricing pressure, intensifying competition, and long-term patent cliffs, but current trajectory supports intermediate-term optimism. Introduction This is my sixth article on Novo Nordisk ( NVO ) since I returned to write on this site in August 2025. My earlier articles, which you can find here , argued that Mr. Market This is my sixth article on Novo Nordisk ( NVO ) since I returned to write on this site in August 2025. My earlier articles, which you can find here , argued that Mr. Market